Shi Jiali, Zhou Jiaqing
Department of Otorhinolaryngology-Head and Neck Surgery, Renji Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, 200127, China.
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2012 Nov;26(21):965-9, 972.
To investigate the accurate marker to detect regulatory T cells in vivo and also to evaluate the changes of CD4+ CD25+ regulatory T cells in peripheral blood from patients with papillary thyroid carcinoma and clinical significance.
Forty patients with papillary thyroid carcinoma and 34 patients with thyroid adenoma were included in this study. The proportion of CD4+ D25+ CD127(low/-) regulatory T cells population and CD4+ CD25+ FoxP3- regulatory T cells population was evaluated by flow cytometric analysis.
Compared with control group, the proportion of CD4+ CD25+ CD127(low/-) regulatory T cells and CD4+ CD25+ FoxP3+ regulatory T cells in PTC group increased significantly (P < 0.05). The proportions of CD4+ CD25+ CD127(low/-) regulatory T cells and CD4+ CD25+ FoxP3+ regulatory T cells were significantly higher between patients with and without cervical lymph node metastasis (P < 0.05), and extraordinarily different among patients with different clinical stages (P < 0.05).
CD4+ CD25+ CD127(low/-) can be used as an effective membrane marker in identification of CD4+ CD25+ regulatory T cells in stead of CD4+ CD25+ FoxP3+. The CD4+ CD25+ regulatory T cells in the peripheral blood of papillary thyroid carcinoma patients are significantly increased in comparison with that in thyroid adenoma patients. The proportions of Treg of patients with different stages, cervical lymph node metastasis are different. It may be responsible for the happen, development and recurrence of the papillary thyroid carcinoma.
探讨在体内检测调节性T细胞的准确标志物，并评估甲状腺乳头状癌患者外周血中CD4+CD25+调节性T细胞的变化及其临床意义。
本研究纳入40例甲状腺乳头状癌患者和34例甲状腺腺瘤患者。采用流式细胞术分析评估CD4+D25+CD127(low/-)调节性T细胞群体和CD4+CD25+FoxP3-调节性T细胞群体的比例。
与对照组相比，PTC组中CD4+CD25+CD127(low/-)调节性T细胞和CD4+CD25+FoxP3+调节性T细胞的比例显著增加（P<0.05）。有和无颈部淋巴结转移的患者之间，CD4+CD25+CD127(low/-)调节性T细胞和CD4+CD25+FoxP3+调节性T细胞的比例显著更高（P<0.05），且在不同临床分期的患者中差异非常显著（P<0.05）。
CD4+CD25+CD127(low/-)可作为鉴定CD4+CD25+调节性T细胞的有效膜标志物，替代CD4+CD25+FoxP3+。与甲状腺腺瘤患者相比，甲状腺乳头状癌患者外周血中的CD4+CD25+调节性T细胞显著增加。不同分期、颈部淋巴结转移患者的Treg比例不同。这可能与甲状腺乳头状癌的发生、发展和复发有关。
